The information highlighted (if any) are the most recent updates for this brand.
The safety of Counterpain-PXM use during pregnancy or lactation has not yet been established. Counterpain-PXM inhibits prostaglandin synthesis and release through a reversible inhibition of the cyclooxygenase enzyme. This effect, as with other nonsteroidal anti-inflammatory agents, has been associated with an increased incidence of dystocia and delayed parturition in pregnant animals when piroxicam administration was continued into late pregnancy. Nonsteroidal anti-inflammatory drugs are also known to induce closure of the ductus arteriosus in infants. A preliminary study indicates that following oral administration, piroxicam exists in maternal milk in a concentration of approximately 1% of that reached in plasma after oral administration. Counterpain-PXM is not recommended for use in nursing mothers as the clinical safety has not been established.
Sign Out
